6-8-dithiooctanoic acid | 1150617-44-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-8-dithiooctanoic acid
• 英文别名: 6,8-Bis(sulfanylidene)octanoic acid
• CAS: 1150617-44-9
• 化学式: C₈H₁₂O₂S₂
• 分子量: 204.314
• InChiKey: UHDFYGJKCPVPNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-8-dithiooctanoic acid 、 (2S,3S,4S,5S)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease

  摘要：

  DOI：

  10.1016/j.bmc.2022.117129

文献信息

• COMPOUND AND METHOD FOR THE TREATMENT OF PAIN
  申请人：KANDULA MAHESH

  公开号：US20110237658A1

  公开（公告）日：2011-09-29

  The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.

  本公开提供了一种化合物的化学式1。本公开还提供了一种合成该化合物的方法。化学式1的化合物或其药用可接受的盐，以及其多晶型、溶剂合物和水合物可以制成药物组合物。化学式1的药物组合物或最终化合物可以制成用于非侵入性口服、局部（例如经皮）、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和静脉途径的方法。这些组合物可用于治疗伴随慢性疾病或其相关并发症表现的慢性疼痛。
• [EN] CONJUGATES OF A LIPOIC ACID DERIVATIVE AND ANTI-PROLIFERATION AGENT AND MEDICAL USES THEREOF<br/>[FR] CONJUGUÉS DE DÉRIVÉ D'ACIDE LIPOÏQUE ET D'AGENT ANTIPROLIFÉRATIF ET LEURS UTILISATIONS MÉDICALES
  申请人：CORNERSTONE PHARMACEUTICALS INC

  公开号：WO2011143593A1

  公开（公告）日：2011-11-17

  The invention provides conjugate compounds, pharmaceutical compositions, therapeutic methods, and kits for use in treating cell proliferation disorders, such as cancer. The conjugates comprise a redox-modulating compound, such as a lipoic acid derivative, chemically bonded to an anti-proliferation agent, such as gemcitabine.

  本发明提供了共轭化合物、制药组合物、治疗方法和用于治疗细胞增殖紊乱（如癌症）的试剂盒。这些共轭物包括氧化还原调节化合物（如硫辛酸衍生物）和抗增殖剂（如吉西他滨）化学键合而成。
• Synthesis of Nitrone‐derived Pyrrolidine Scaffolds and Their Combinatorial Libraries to Develop Selective α‐ <scp>l</scp> ‐Rhamnosidase Inhibitors
  作者：Wei‐An Chen、Huang‐Yi Li、Ashik Sayyad、Chun‐Yen Huang、Wei‐Chieh Cheng

  DOI：10.1002/asia.202200172

  日期：2022.7.15

  efficient strategy to develop selective α-l-rhamnosidase inhibitors is described. Five functionalized pyrrolidine scaffolds were rationally designed and synthesized from cyclic nitrones. Their corresponding diverse libraries prepared by combinatorial chemistry enable us to increase the chemical space of pyrrolidine-based iminosugars and allow us to identify selective and potent α-l-rhamnosidase inhibitors

  描述了开发选择性α- l-鼠李糖苷酶抑制剂的有效策略。以环状硝酮为原料，合理设计并合成了五种功能化吡咯烷支架。通过组合化学制备的相应的多样化文库使我们能够增加基于吡咯烷的亚胺糖的化学空间，并使我们能够鉴定选择性且有效的α- l-鼠李糖苷酶抑制剂。
• [EN] FATTY ACIDS<br/>[FR] ACIDES GRAS
  申请人：SHORR ROBERT

  公开号：WO2010110887A1

  公开（公告）日：2010-09-30

  Organic metabolites are produced in vivo from derivatives of thiol-containing alkyl fatty acids, such as but not limited to lipoic acid. These metabolites are intended to perturb at least one enzyme or enzyme complex, receptor, ion channel, transport protein, or at least one subunit of each thereof, such as lipoate-containing or -utilizing dehydrogenase complexes and/or other enzymes. These metabolites are also intended to influence reactions which generate and/or regulate reactive oxygen and nitrogen species and/or other associated signal transduction pathways and cascades. The target enzymes, receptors, channels, proteins, reactions, pathways, and cascades are found in the organelles of diseased cells of warm-blooded animals, including but not limited to cancer cells. Also produced are structures which are resistant to or prevented from being metabolized into these metabolites, as well as a pharmaceutically-acceptable carrier formed from such metabolites, and methods of use thereof.

  有机代谢物是在体内从含巯基的烷基脂肪酸衍生物中产生的，例如丙二酸等。这些代谢物旨在扰乱至少一个酶或酶复合物、受体、离子通道、转运蛋白或其中至少一个亚单位，例如含丙二酸或利用丙二酸的脱氢酶复合物和/或其他酶。这些代谢物还旨在影响生成和/或调节活性氧和氮物种和/或其他相关信号转导途径和级联反应。目标酶、受体、通道、蛋白质、反应、途径和级联反应可在温血动物的疾病细胞的细胞器中找到，包括但不限于癌细胞。还产生了抵抗或防止被代谢成这些代谢物的结构，以及由这些代谢物形成的药学可接受载体和使用方法。
• LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING PROCESS
  申请人：OOHASHI Hidekazu

  公开号：US20110054212A1

  公开（公告）日：2011-03-03

  A lithographic printing plate precursor, which comprises: a support; an image-recording layer; and a protective layer, in this order, wherein at least one of the image-recording layer and the protective layer comprises a phosphonium salt having a specific structure, and a lithographic printing process, which comprises: exposing a lithographic printing plate precursor; supplying an oil-based ink and a fountain solution comprising a phosphonium salt having a specific structure to the exposed lithographic printing plate precursor on a printing machine to remove an unexposed area of an image-recording layer; and conducting printing.

  一种光刻印刷版前体，包括：支撑体；图像记录层；以及保护层，依次排列，其中图像记录层和保护层中至少有一层包含具有特定结构的磷酸铵盐；以及一种光刻印刷工艺，包括：曝光光刻印刷版前体；在印刷机上向曝光的光刻印刷版前体提供具有特定结构的磷酸铵盐的油墨和喷泉溶液，以去除图像记录层中未曝光区域；进行印刷。